Orelabrutinib, a selective BTK inhibitor, has shown promise for B-cell malignancies, particularly CNS lymphomas, but its efficacy and safety in PTLD, especially at lower doses, have not been established (3). Here, BTK is linked to post-transplant lymphoproliferative disease.